1
POPSPatients 'free from cancer' after immune-boost treatment The drug, which has been developed by Micromet, in Bethesda, Maryland, was trialled by a team led by Dr Ralf Bargou at University of Würzburg in Würzburg, German. Of the 38 patients with non-Hodgkin’s lymphoma who took part in the most recent study, two of the seven who received the highest doses of the drug saw their cancer disappear while five others had reductions in their tumours of more than 50 per cent. One patient on a lower dose also became cancer free and remains so after more than a year. The results, published in the journal Science, are encouraging because they suggest that the bigger the dose, the bigger the effect.